Skip to main content

Relation of resistin to proprotein convertase subtilisin–kexin type 9 levels in coronary artery disease patients with different nutritional status

Journal of Endocrinological Investigation volume 38, pages 1291–1299 (2015)Cite this article

Abstract

Objective

To investigate the association of resistin with proprotein convertase subtilisin–kexin type 9 (PCSK9) levels, another novel regulator of atherosclerosis, in the condition of coronary artery disease (CAD).

Research design and methods

We prospectively enrolled a total of 356 consecutive stable CAD patients who were not treated with lipid-lowering drugs in the present study. The baseline clinical characteristics were collected. Plasma PCSK9 and resistin levels were determined by ELISA. The relationship between plasma PCSK9 and resistin levels was investigated.

Results

Overall, plasma resistin exhibited a positive nonparametric correlation with PCSK9 levels (r = 0.123, p = 0.02). When the patients were classified into groups based on body mass index (BMI), the resistin correlated significantly to the PCSK9 levels in patients with BMI < 25 kg/m2 (r = 0.162, p = 0.026) but not in patients with BMI ≥ 25 kg/m2 (r = 0.087, p = 0.205). Multivariate regression analysis corroborated the relation between the PCSK9 and an elevated resistin level in patients with BMI < 25 kg/m2 independently of traditional parameters including age, sex, BMI, smoking, family history of CAD, systolic blood pressure, glucose, low density lipoprotein cholesterol, white blood cell, neutrophil to lymphocyte ratio, and high-sensitive C-reactive protein.

Conclusions

Plasma resistin was positively related to PCSK9 levels in CAD patients with normal weight, suggesting that the circulating resistin might represent a link with PCSK9 level variations in CAD progression of normal body weight.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1

Abbreviations

CAD :

Coronary artery disease

BMI :

Body mass index

SBP :

Systolic blood pressure

DBP :

Diastolic blood pressure

TC :

Total cholesterol

LDL-C :

Low density lipoprotein cholesterol

HDL-C :

High density lipoprotein cholesterol

Apo :

Apolipoprotein

WBC :

White blood cell

NLR :

Neutrophil to lymphocyte ratio

hs-CRP :

High-sensitive C-reactive protein

PCSK9 :

Proprotein convertase subtilisin/kexin type 9

References

  1. Mendis S, Chestnov O (2014) The global burden of cardiovascular diseases: a challenge to improve. Curr Cardiol Rep 16(5):486

    Article  PubMed  Google Scholar 

  2. Wang JC, Bennett M (2012) Aging and atherosclerosis: mechanisms, functional consequences, and potential therapeutics for cellular senescence. Circ Res 111(2):245–259

    CAS  Article  PubMed  Google Scholar 

  3. van Diepen JA, Berbee JF, Havekes LM et al (2013) Interactions between inflammation and lipid metabolism: relevance for efficacy of anti-inflammatory drugs in the treatment of atherosclerosis. Atherosclerosis 228(2):306–315

    Article  PubMed  Google Scholar 

  4. Steppan CM, Bailey ST, Bhat S et al (2001) The hormone resistin links obesity to diabetes. Nature 409(6818):307–312

    CAS  Article  PubMed  Google Scholar 

  5. Holcomb IN, Kabakoff RC, Chan B et al (2000) FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. EMBO J 19(15):4046–4055

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  6. de Luis DA, Sagrado MG, Conde R et al (2010) Relation of resistin levels with cardiovascular risk factors, insulin resistance and inflammation in naive diabetes obese patients. Diabetes Res Clin Pract 89(2):110–114

    Article  PubMed  Google Scholar 

  7. Melone M, Wilsie L, Palyha O et al (2012) Discovery of a new role of human resistin in hepatocyte low-density lipoprotein receptor suppression mediated in part by proprotein convertase subtilisin/kexin type 9. J Am Coll Cardiol 59(19):1697–1705

    CAS  Article  PubMed  Google Scholar 

  8. Abifadel M, Varret M, Rabes JP et al (2003) Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34(2):154–156

    CAS  Article  PubMed  Google Scholar 

  9. Lambert G, Charlton F, Rye KA et al (2009) Molecular basis of PCSK9 function. Atherosclerosis 203(1):1–7

    CAS  Article  PubMed  Google Scholar 

  10. Stein EA, Raal FJ (2013) Insights into PCSK9, low-density lipoprotein receptor, and low-density lipoprotein cholesterol metabolism: of mice and man. Circulation 127(24):2372–2374

    Article  PubMed  Google Scholar 

  11. Wu NQ, Li JJ (2014) PCSK9 gene mutations and low-density lipoprotein cholesterol. Clin Chim Acta 431:148–153

    CAS  Article  PubMed  Google Scholar 

  12. Kwakernaak AJ, Lambert G, Dullaart RP (2012) Relationship of proprotein convertase subtilisin-kexin type 9 levels with resistin in lean and obese subjects. Clin Biochem 45(16–17):1522–1524

    CAS  Article  PubMed  Google Scholar 

  13. Hampton EN, Knuth MW, Li J et al (2007) The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain. Proc Natl Acad Sci 104(37):14604–14609

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  14. Rashid S, Kastelein JJ (2013) PCSK9 and resistin at the crossroads of the atherogenic dyslipidemia. Expert Rev Cardiovasc Ther 11(11):1567–1577

    CAS  Article  PubMed  Google Scholar 

  15. Li S, Guo YL, Xu RX et al (2014) Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease. Atherosclerosis 234(2):441–445

    CAS  Article  PubMed  Google Scholar 

  16. Li S, Guo YL, Xu RX et al (2014) Plasma PCSK9 levels are associated with the severity of coronary stenosis in patients with atherosclerosis. Int J Cardiol 174:873–874

    Article  Google Scholar 

  17. Guo YL, Liu J, Xu RX et al (2013) Short-term impact of low-dose atorvastatin on serum proprotein convertase subtilisin/kexin type 9. Clin Drug Investig 33(12):877–883

    CAS  Article  PubMed  Google Scholar 

  18. Li JJ, Nie SP, Qian XW et al (2009) Chronic inflammatory status in patients with coronary artery ectasia. Cytokine 46(1):61–64

    CAS  Article  PubMed  Google Scholar 

  19. Hong LF, Li XL, Luo SH et al (2014) Relation of leukocytes and its subsets counts with the severity of stable coronary artery disease in patients with diabetic mellitus. PLoS ONE 9(3):e90663

    PubMed Central  Article  PubMed  Google Scholar 

  20. Baass A, Dubuc G, Tremblay M et al (2009) Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. Clin Chem 55(9):1637–1645

    CAS  Article  PubMed  Google Scholar 

  21. Cariou B, Le May C, Costet P (2011) Clinical aspects of PCSK9. Atherosclerosis 216(2):258–265

    CAS  Article  PubMed  Google Scholar 

  22. Steppan CM, Lazar MA (2004) The current biology of resistin. J Intern Med 255(4):439–447

    CAS  Article  PubMed  Google Scholar 

  23. Bo S, Gambino R, Pagani A et al (2005) Relationships between human serum resistin, inflammatory markers and insulin resistance. Int J Obes (Lond) 29(11):1315–1320

    CAS  Article  Google Scholar 

  24. Shetty GK, Economides PA, Horton ES et al (2004) Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 27(10):2450–2457

    CAS  Article  PubMed  Google Scholar 

  25. Ohmori R, Momiyama Y, Kato R et al (2005) Associations between serum resistin levels and insulin resistance, inflammation, and coronary artery disease. J Am Coll Cardiol 46(2):379–380

    Article  PubMed  Google Scholar 

  26. Reilly MP, Lehrke M, Wolfe ML et al (2005) Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 111(7):932–939

    CAS  Article  PubMed  Google Scholar 

  27. Jamaluddin MS, Weakley SM, Yao Q et al (2012) Resistin: functional roles and therapeutic considerations for cardiovascular disease. Br J Pharmacol 165(3):622–632

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  28. Choi HY, Kim S, Yang SJ et al (2011) Association of adiponectin, resistin, and vascular inflammation: analysis with 18F-fluorodeoxyglucose positron emission tomography. Arterioscler Thromb Vasc Biol 31(4):944–949

    CAS  Article  PubMed  Google Scholar 

  29. Urban D, Poss J, Bohm M et al (2013) Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. J Am Coll Cardiol 62(16):1401–1408

    CAS  Article  PubMed  Google Scholar 

  30. Hotamisligil GS (2003) The irresistible biology of resistin. J Clin Invest 111(2):173–174

    PubMed Central  CAS  Article  PubMed  Google Scholar 

Download references

Acknowledgments

This work was partially supported by the National Natural Scientific Foundation (81070171, 81241121), the Specialized Research Fund for the Doctoral Program of Higher Education of China (20111106110013), the Capital Special Foundation of Clinical Application Research (Z121107001012015), the Capital Health Development Fund ( 2011400302), and the Beijing Natural Science Foundation (7131014) awarded to Dr. Jian-Jun Li, MD, PhD.

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Author information

Affiliations

  1. Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, BeiLiShi Road 167, Beijing, 100037, China

    S. Li, R. X. Xu, Y. Zhang, Y. L. Guo, C. G. Zhu, G. Liu, Q. Dong & J. J. Li

Authors
  1. S. Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. X. Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y. Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y. L. Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. G. Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Q. Dong
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J. J. Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. J. Li.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Li, S., Xu, R.X., Zhang, Y. et al. Relation of resistin to proprotein convertase subtilisin–kexin type 9 levels in coronary artery disease patients with different nutritional status. J Endocrinol Invest 38, 1291–1299 (2015). https://doi.org/10.1007/s40618-015-0310-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40618-015-0310-y

Keywords

  • Proprotein convertase subtilisin/kexin type 9
  • Resistin
  • Coronary artery disease
  • Obesity